Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

About this update from Marker Therapeutics, Inc.

[{"type":"image","alt":"Marker Therapeutics","displaySize":"","headline":null,"caption":"Marker Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":81,"url":"https://media.zenfs.com/en/globenewswire.com/c653d0561d7f95598e7d67143dc80360"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0mY3DR01OO92qj7fFLjFyw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c653d0561d7f95598e7d67143dc80360","width":300,"height":81}},"lazy":false},{"type":"text","content":"HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format on February 25-26, 2026.","length":477,"tagName":"p"},{"type":"text","content":"Presentation Details: ","length":21,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Event:","length":6,"tagName":"p","attribs":{}}]},{"style":"border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;vertical-align:top;","val":[{"type":"text","content":"Oppenheimer 36th Annual Healthcare Life Sciences Conference","length":59,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Date: ","length":5,"tagName":"p","attribs":{}}]},{"style":"border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Wednesday, February 25, 2026","length":28,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:...

More updates from Marker Therapeutics, Inc.